The Special Investment Facilitation Council (SIFC) has facilitated a major breakthrough in Pakistan’s health sector, enabling the country’s first drug testing laboratory under the Drug Regulatory Authority of Pakistan (DRAP) to secure prequalification from the World Health Organization (WHO).
The achievement marks a significant step forward in strengthening Pakistan’s pharmaceutical regulatory framework and enhancing global confidence in its drug quality assurance systems.
According to official details, the state-of-the-art drug testing laboratory will be established in Karachi and will operate under DRAP’s administration. The milestone follows extensive coordination at both domestic and international levels, led by SIFC to overcome regulatory and technical challenges.
The WHO prequalification signifies that the facility meets international standards for quality, safety, and reliability in drug testing.
Boost to exports and investor confidence
Experts believe the accreditation will significantly improve Pakistan’s standing in global pharmaceutical markets, potentially increasing exports by ensuring internationally recognized testing and compliance standards.
The development is also expected to strengthen investor confidence in Pakistan’s pharmaceutical manufacturing sector, as companies will benefit from improved regulatory support and local testing capabilities.
With the establishment of the WHO-recognized facility, Pakistan will be able to conduct high-quality drug testing domestically, reducing dependence on foreign laboratories and lowering associated costs and delays.
Officials say the milestone reflects broader efforts toward regulatory modernization and institutional strengthening within Pakistan’s health sector.
SIFC’s role in facilitating coordination between stakeholders has been highlighted as a key factor in achieving the breakthrough, reinforcing its growing influence in advancing strategic economic and sectoral initiatives.
